CORRECTING and REPLACING Ocular Therapeutix™ Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Subhead of release should read: DEXTENZA® (dexamethasone ophthalmic insert) is the First Intracanalicular Insert for Drug Delivery (instead of DEXTENZA® (dexamethasone ophthalmic insert) is the First Intracanalicular Insert Approved by the FDA for Drug Delivery). The corrected release reads: OCULAR THERAPEUTIX™ ANNOUNCES FDA APPROVAL OF DEXTENZA® FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY DEXTENZA® (dexamethasone ophthalmic insert) is the Firs